From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults

Table 3 Drug resistance mutations and loss of protease inhibitor (PI) drug options among patients with any major PI mutation

Patient ID	Sex	Age (years)	Viral load (copies/ml)	CD4 (cells/mm³)	Duration on ART (years)	Duration on second line ART (years)	HIV-1 sub-type	Identified drug resistance mutations			Level of PI resistance
Patient ID	Sex	Age (years)	Viral load (copies/ml)	CD4 (cells/mm³)	Duration on ART (years)	Duration on second line ART (years)	HIV-1 sub-type	NNRTI	NRTI	PI	High	Intermediate	Low	Susceptible
CoL-1	M	57	339,081	165	9.4	3.6	A		M184V, K65R, A62V	V82S, I54V, M46I, K43T, L24IL, L10F	ATV, FPV, IDV, LPV, NFV	SQV, TPV		DRV
CoL-2	F	58	3886	620	9.3	6.2	A		M184V	V82A, I54V, M46L, L89V, L10F	ATV, FPV, IDV, LPV, NFV	SQV	TPV	DRV
CoL-3	M	38	13,560	130	9.4	6.6	D	A98G, L100I, K103N	M41L, T215Y, L74V	V82A, I54IV, L33F		ATV, FPV, IDV, SQV	LPV, NFV, TPV	DRV
CoL-4	M	34	221,251	130	9.0	6.7	D		M184V, M41L, T215Y	V82A, I54V, M46I, L33F, L24I, L10F	ATV, FPV, IDV, LPV, NFV	SQV	TPV	DRV
CoL-5	M	69	14,127	287	9.2	7.2	A	K103N		V82A		IDV, NFV	ATV, FPV, LPV, SQV	DRV,TPV
CoL-6	F	39	68,537		9.8	7.3	D	K103N, L100I, Y181F	M184L, L74V, M41LM, T215A	V82AV, A71T, L10I, K20T		IDV, LPV, NFV	ATV, FPV, SQV	DRV, TPV
CoL-7	F	40	98,489	97	9.0	7.8	D	G190A, Y181C, K101E	M41L, L210W, K219E, T215C	V82F, I54V, M46I, Q58E, I47V, L10I	IDV, FPV, LPV, NFV	ATV, TPV	DRV, SQV

F Female, M Male, PI Protease inhibitor, NRTI Nucleoside Reverse Transcriptase Inhibitor, NNRTI Non-Nucleoside Reverse Transcriptase Inhibitor, ATV Atanazavir, DRV Darunavir, FPV Fosamprenavir, IDV Indinavir, LPV Lopinavir, NFV Nelfinavir, SQV Saquinavir, TPV Tipranavir

ISSN: 1756-0500